Written answer
Medicinal Products
New 2026–2029 agreements target 180-day reimbursement decisions by Q1 2029, while Deloitte’s end-to-end review is underway and expected to take nine months.
188. Deputy Micheál Carrigy asked the Minister for Health the progress on the changing of the reimbursement process for new medicines. [74517/26]
Comment on this
Delivering timely access to medicines for patients is a priority for Government.
Two new Framework Agreements on the Supply and Pricing of Medicines (FASPM) between the State and Medicines for Ireland and the Irish Pharmaceutical Health Association respectively were signed on the 3rd of March for the period 2026-2029.
These Agreements include a commitment and a structured process towards achieving a 180-day timeline for reimbursement decisions by Q1 2029, accelerating patient access to new treatments.
In line with these agreements the Minister for Health commissioned a strategic end to end review of the Irish medicines pricing and reimbursement process and its functioning.
The review is considering every stage of the pricing and reimbursement process, including periods prior to application to the HSE and following reimbursement decision. The tender process for the end-to-end review has now concluded with Deloitte LLP identified as the successful applicant with the aim to have the review completed within an anticipated completion timeframe of 9 months following the start of the contract. Engagement between Deloitte LLP and all stakeholders in the process have now commenced and this work is ongoing.
Along with the other measures outlined in the Framework Agreements, implementation of recommendations arising from the end-to-end review will contribute to enabling faster reimbursement decisions for new medicines.